We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Hypoxia in Mesenchymal Stem Cell

Wahyu Widowati, Dwi Davidson Rihibiha,
Khie Khiong, M. Aris Widodo,
Sutiman B. Sumitro and Indra Bachtiar

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/65510>

Abstract

Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent stem cells with self-renewal properties and ability to differentiate into a variety of mesenchymal tissues. This chapter overviews effects of hypoxia on MSCs, makes it promising therapy to various diseases. Cultivation of MSCs under hypoxic condition results in variety of outcome that is important to be noted in clinical use. In most studies, hypoxic condition appears to increase proliferation, differentiation, and immune regulatory performance of MSCs without affecting its characteristic. Those benefits are therefore utilized in clinical application. However, there are also studies that report on negative effects of hypoxia in MSCs such as chromosomal instability. Molecular mechanism of MSCs in hypoxic condition is provided for better understanding, which is crucial for further development with better outcome.

Keywords: mesenchymal stem cells, hypoxia

1. Introduction

In these days, stem cell therapy is becoming more believable in treating degenerative diseases compared to conventional medicine. Various diseases such as diabetes, myocardial infarction, spinal cord injury, stroke, and Parkinson's and Alzheimer's diseases have become more prevalent with increasing life expectancy. It has been estimated that in the United States alone, ~128 million individuals would benefit from regenerative stem cell therapy during their lifetime. Mesenchymal stem cells (MSCs) have been highly utilized to treat degenerative diseases among other stem cells. These cells are found in tissues such as bone marrow, adipose tissue, umbilical cord,

and dental pulp. Self-renewal and multipotency are the key features of MSCs that make it promising tool. These properties have raised interest on researchers for finding appropriate method to optimize the genetic and environmental factors, which later enhance the biological activities of MSCs.

Many researches have been conducted in the last two decades to study the complex processes in stem cell maintenance. The role of hypoxic conditions (usually 2–9% O₂ concentration) on stem cell biology is very interesting subject due to its beneficial effects. Thus, cultivation of MSCs under hypoxia is currently studied to obtain better understanding, as well as further development to generate better outcome.

2. Mesenchymal stem cell

About 130 years ago, German pathologist Conheim proposed the presence of non-hematopoietic stem cells in the bone marrow that contributes to wound healing in numerous peripheral tissues. Later in the early 1970s, Friedenstein and colleagues demonstrated that the rodent bone marrow had fibroblastoid cells with clonogenic potential *in vitro* [1, 2]. In the study, after the non-adherent cells were removed a few hours later, spindle-like cells, which were morphologically heterogeneous, appeared to attach to the plastic, capable of forming colonies. These cells could also make bone and reconstitute a hematopoietic microenvironment in subcutaneous transplants. Moreover, they could regenerate heterotopic bone tissue in serial transplants, thus indicated their self-renewal potential. Over the years, many studies have investigated these findings and found that these cells were also present in the human bone marrow and could be sub-passaged and differentiated *in vitro* into a variety of the mesenchymal lineages such as osteoblasts, chondrocytes, adipocytes, and myoblasts [3–7]. It has been further renamed as “mesenchymal stem cell” or MSC [4].

MSCs or MSC-like cells are also found in fat, umbilical cord blood, amniotic fluid, placenta, dental pulp, tendons, synovial membrane, and skeletal muscle, yet the complete equivalency of such populations remains unclear [8–16]. Characteristic of MSCs according to The International Society for Cell Therapy [17] consists of (1) adherence to plastic in standard culture conditions; (2) expression of the surface molecules CD73, CD90, and CD105 in the absence of CD34, CD45, HLA-DR, CD14 or CD11b, CD79a, or CD19 surface molecules; and (3) a capacity for differentiation to osteoblasts, adipocytes, and chondroblasts *in vitro*. These criteria were established to standardize human MSC isolation but may not apply uniformly to other species. For instance, marker expression and behavior in murine MSCs were different compared to human MSCs [18]. Certain *in vivo* surface markers may no longer be expressed after Transplantation, although new markers are obtained during expansion. In study done by Jones et al., MSC uniformly expressed HLA-DR (a marker that should not be expressed on MSCs by the above definition) while also expressing CD90 and CD105, adhering to plastic in culture, and differentiating into osteoblasts, adipocytes, and chondroblasts [19]. Indeed, clear definition of MSC-specific characteristics is difficult to apply in both human and animal models.

3. Hypoxia in mesenchymal stem cell

Numerous *in vitro* studies have been conducted in the last two decades to observe the complex processes in stem cell maintenance. However, the role of physiologically hypoxic conditions (usually 2–9% O₂ concentration) on stem cell biology received very little attention. O₂ concentration is an environmental factor that plays a vital role on stem cell fate and function [20]. Stem cells are typically cultured under the ambient O₂ concentration without paying attention to the metabolic milieu of the niche in which they normally grow [21]. The effects of different O₂ levels in MSC culture were first studied in 1958, when Cooper et al. and Zwartouw and Westwood observed that some cells proliferated more rapidly under low O₂ tension levels compared to normal atmospheric levels [22, 23]. MSCs are present in perivascular niches in close association with blood vessels in virtually all tissues [11, 16, 24] and have been compared to pericytes [25]. Even though MSCs are located close to vascular structures, the different tissues where these stem cells are found exhibit low oxygen tensions [26–29]. Therefore, it is possible that maintaining MSCs in an undifferentiated state may require a hypoxic environment, in addition to other factors.

The higher O₂ concentration might cause environmental stress to the *in vitro* cultured MSCs. Recent studies have presented significant evidences regarding the negative outcome under ambient O₂ concentration on MSCs, including early senescence, longer population doubling (PD) time, DNA damage [30, 31], and poor engraftment following transplantation [32, 33]. These have shown the influential effect of O₂ concentration on MSCs biology and raised serious concern over its therapeutic efficiency and biosafety. Thus, the effect of different O₂ concentration on MSCs biology is further discussed based on recent research outcomes.

4. Characteristic of MSCs in hypoxic condition

As described above, MSC immunophenotype is characterized by the expression of CD73, CD90, CD105, CD106, CD146, and MHC class I molecules, and the absence of markers such as CD45 and CD34 or MHC class II molecules [17]. Many studies suggest that hypoxia has no effect on MSCs characteristic, indicated by surface markers. According to one study by Holzwarth et al., there were no significant differences in the expression of cell surface markers after 14 days of culture at 1% when compared to 20% of O₂ [34]. Referring to study carried out by Nekanti et al., WJ-MSCs cultured under both hypoxia and normoxia for 10 passages were positive for CD44, CD73, CD90, CD105, and CD166 and negative for CD34, CD45, and HLA-DR, and there was no significant difference between the two populations [35]. These results are also supported by study carried out by Widowati et al. The surface marker of WJ-MSCs of P4 and P8 both normoxic and hypoxic 5% O₂ were not significantly different. WJ-MSCs were positive for CD105, CD73, and CD90 and negative for CD34, CD45, CD14, CD19, and HLA-II [36].

Morphology changes are also documented in MSCs under hypoxia. Referring to Nekanti et al., WJ-MSC cultured under hypoxia showed a higher amount of large, flattened cells both at

early and late passages, compared to normoxic cultures. The enlargement in cell size under hypoxia might be due to a natural response to low oxygen, in which increased surface area would allow for an increase in oxygen diffusion rate [35].

5. MSCs proliferation in hypoxic condition

Capability for self-renewal is a key feature of stem cells. An increased proliferation rate is necessary for more efficient use of stem cells in regenerative therapies. Fehrer et al. demonstrated that bone marrow-derived MSCs (BM-MSCs) cultured in 3% O₂ concentration showed significant increased *in vitro* proliferative lifespan, with ~10 additional population doublings (PDs) (28.5 ± 3.8 PD in 20% O₂ and 37.5 ± 3.4 PD in 3% O₂) before reaching senescence compared to cells cultured in the ambient O₂ environment [31]. In addition, early passaged MSCs cultured in hypoxic conditions also exhibit increased proliferative lifespan along with significant difference in population doubling [30]. Furthermore, it is possible to harvest more than 1×10^9 MSCs from the first five passages cultured in 3% O₂, whereas in ambient condition only 2×10^7 cells can be obtained [30]. Higher *in vitro* expansion rate in hypoxic conditions has also been reported by other researchers [37–39]. Such *in vitro* culture environment also allows to maintain a higher proportion of rapidly self-renewing MSCs for a longer period of time [40]. Other study showed that the increased hypoxic (O₂ 2.5%) condition was the best microenvironment for stem cell proliferation compared to normoxic and hypoxic (O₂ 5%) for cells at a high passage (P7, P8) [41].

However, various responses of stem cells under hypoxia have been reported [42]. Those differences in cellular responses on hypoxia might be associated with degrees and durations of hypoxia, as well as other cell conditions. Oxygen tension in the stem cell niche for MSCs is suggested to be various from 1 to 7% [43]. A study by Holzwarth et al. showed that rates of MSCs proliferation were reduced after 7 days of culture under hypoxia at 21, 5, 3, and 1% O₂. In their study, only 1.37% of the cells entered the G2/M phase in hypoxic cultures (1% O₂) after 7 days, compared to 2.50% at hyperoxic culture (21% O₂). Reduced O₂ concentrations were therefore confirmed to inhibit cell proliferation as indicated by reduced number of cells in the G2/M phase [34].

6. Chromosomal stability of MSCs in hypoxic condition

Some recent studies have found that human mesenchymal stem cells (hMSCs) retained chromosomal stability following long-term culture *in vitro* [44–46]. Hypoxic environments have shown to increase mutation frequencies in cancer cell lines and trigger genomic rearrangements [47, 48]. It is suggested that oxygen concentration has a major impact on karyotypic aberration. Referring to study of Ueyama et al., chromosomal instability is associated with repeated cell division. A high frequency of chromosomal abnormality breakpoints in common fragile sites (CFSs) was detected by karyotypic analysis (e.g., 2q33, 7q11, 7q36, 8q22.1, 8q24.1,

11p15.1, 19q13) [49]. Generally, chromosomes have fragile sites that are prone to exhibiting gaps and breaks during metaphase [50], in which chromosome rearrangement occurs in cultured cells. Fragile sites are categorized into two main classes, common and rare, according to their frequency in the population [51]. In Ueyama study, several genes involved in regulation of the cell cycle, transcription and cell adhesion, are located in that region with a frequency of 6, 5, and 2%, respectively. In particular, the 11p15.5 domain known as an important tumor suppressor gene region such as tetraspanin 32 (TSPAN32) and tumor-suppressing subtransferable candidate 4 (TSSC4) is present in this region. Alterations in this region have been associated with some neoplasia. It is suggested that the deletion of contiguous genes may induce a multisystem developmental disorder and that these alterations might influence normal functioning and cell survival.

Sex chromosome aneuploidy was also one of the most observed aberrational karyotypes. Frequency of sex chromosome in cultured lymphocytes was significantly higher in females than in males, and that loss of Y chromosomes correlated with age in human bone marrow cells [52, 53]. There are several factors influencing karyotypic stability such as hypoxic culture conditions, donor age, and multiple passages. Karyotypic aberrations increased with passage number and hMSCs undergo spontaneous transformation with tumorigenic potential, especially in later passages under hypoxic culture conditions in hMSCs of elderly donors [49]. Shortly, monitoring of chromosomal stability in culture expanded hMSCs is required prior to exposure to human beings, in order to detect mutations and potentially immortalized clones and to prevent transplant-associated tumor formation.

7. MSCs plasticity in hypoxic condition

The multilineage potential of MSCs is one of the reasons underlying their use in regenerative medicine [54]. Results of MSC differentiation into other lineages diverse according to several studies [34, 55, 56]. Some *in vitro* studies have shown that cultures with low O₂ concentrations stimulated cells to differentiate into adipogenic, osteogenic, or chondrogenic cells. Previous study showed that Rat mesenchymal stem cells (rMSCs) cultured in 5% oxygen produced more bone than cells cultured in 20% O₂ throughout their cultivation time, as indicated by increased markers of osteogenesis, including alkaline phosphatase activity, calcium content, and von Kossa staining. These markers were usually elevated above basal levels when cells were switched from control to low oxygen at first passage and decreased for cells switched from low to control oxygen [57]. Hypoxia appears to exert a potent lipogenic effect independent of PPAR- γ 2 maturation pathway [58]. The level of differentiated antigen H-2Dd and the number of G2/S/M phase cells increased evidently under 8% O₂ condition. Also, the proportion of wide, flattened, and epithelial-like cells increased significantly in MSCs. When cultured in adipogenic medium, there was a fivefold to sixfold increase in the number of lipid droplets under hypoxic conditions compared with that in normoxic culture. Oct4 was downregulated under 8% O₂ condition but still expressed after adipocyte differentiation in normoxic culture and treated with hypoxia-mimicking agents, cobalt chloride (CoCl₂) and deferoxamine mesylate

(DFX). These findings indicate that hypoxia enhances MSC differentiation and hypoxia and hypoxia-mimicking agents generate different effects on MSC differentiation [59].

Conversely, some others have reported suppressive effects of low O₂ tension levels on the plasticity of MSCs. Differentiation capacity into adipogenic progeny was diminished, and no osteogenic differentiation was detected at 3% oxygen. In turn, MSC that had previously been cultured at 3% oxygen could subsequently be stimulated to successfully differentiate at 20% oxygen [31]. Temporary exposure of MSCs to hypoxia resulted in (i) persistent (up to 14 days postexposure) downregulation of *cbfa-1/Runx2*, *osteocalcin*, and type I collagen and (ii) permanent (up to 28 days postexposure) upregulation of *osteopontin* mRNA expressions [60]. Another study by Widowati et al. showed both *nor-WJ-MSCs* and *hypo-WJ-MSCs* differentiated to osteocytes, chondrocytes, and adipocytes, although there was no significant difference among treatments [36]. Study conducted by Georgi et al. showed that molecular fingerprints of human MSCs, primary chondrocytes, and MSC/primary chondrocytes coculture differ when cultured in either normoxic (21% O₂) or hypoxic (2.5% O₂) conditions [61]. In the study, cartilage formation increased in cocultures of MSCs and primary chondrocytes was lost when the cells were cultured under hypoxia which was associated with a decrease in the mRNA expression of the chondrogenic marker *SOX9* and *FGF-1*. This coincided with a significant decrease in lipids. Lipid profiles of normoxic and hypoxic cultures are different. The improved cartilage formation in cocultures of MSCs and chondrocytes may employ soluble factors, including small molecules, lipids, or proteins [62]. Lipids such as phospholipids, cholesterol, and diacylglycerols play significant roles in cellular signaling, membrane integrity, and metabolism [63]. Recent study described that short-term changes in sphingolipid metabolism resulted in long-term effects on the chondrogenic phenotype, and the stimulation of chondrocytes with *acylceramidase* improves cartilage repair and MSC differentiation [64].

8. Immunomodulatory effects of MSCs in hypoxic condition

One of the key factors of MSC in therapeutics development is their known anti-inflammatory/immunomodulatory properties. Clinical studies showed efficacy of MSC at inhibiting lethal, immune-based condition of graft versus host disease [65–70]. It has been reported that MSCs derived from adipose, bone marrow, and placenta have the capability to recover ischemic injury by increasing vascularization and reducing inflammation in ischemia-injured hindlimb, lung, heart, and brain [71–73]. Thus, these cells have been used in clinical trials to treat ischemic disease [74]. MSCs produce a broad variety of cytokines, chemokines, and growth factors that may potentially be involved in tissue repair. Hypoxia increases the production of several of these factors, although different responses are also noted in few studies. Referring to Chang et al., hypoxic preconditioning enhances the capacity of the secretome obtained from cultured human MSCs to release several of these factors and the therapeutic potential of the cultured MSC secretome in experimental TBI [75].

One of the most studied mechanisms of inflammation-induced MSC activity is treatment with interferon gamma (IFN- γ). This cytokine is usually secreted during inflammatory Th1 immune

responses that are associated with autoimmunity mediated by cellular means, such as CD8 T cells and NK cells, which commonly occur in multiple sclerosis, diabetes type 1, and rheumatoid arthritis [76]. Treatment of IFN- γ in MSC has been reported to enhance the immunosuppressive activity through stimulation of the enzyme IDO [77–80]. MSC expression of the tryptophan-catabolizing enzyme indolamine 2,3 deoxygenase (IDO) was markedly upregulated under hypoxia [81]. IDO is critical in immune regulation by MSC through induction of T cell anergy [82] and stimulation of T regulatory cells (T-regs) [83, 84].

Moreover, IFN- γ induced secretion of other inhibitors of inflammation by MSCs, including the complement inhibitor factor H [85], as well as the immunomodulatory molecules TGF- β and HGF [86]. At a functional level, Noone et al. demonstrated that IFN- γ pretreatment of MSC resulted in protection of MSCs from NK-mediated killing via upregulation of prostaglandin E (PGE)-2 synthesis [87]. IFN- γ , along with necrosis factor-alpha (TNF- α), IL-1 α , and IL-1 β , induces Gal-9 in MSC [88].

Another inflammatory mediator known to induce regenerative activities in MSC is the macrophage-derived cytokine TNF- α . Pretreatment of TNF- α in MSCs provided superior angiogenic activity *in vitro*, as indicated by expression of VEGF, as well as *in vivo* in an animal model of critical limb ischemia, as compared to untreated MSCs [89]. In other study, TNF- α preconditioning increased proliferation, mobilization, and osteogenic differentiation of MSCs and upregulated bone morphogenetic protein-2 (BMP-2) protein level. Osteogenic differentiation of MSC induced by TNF- α was partially inhibited after BMP-2 knockdown by siRNA [90]. Lipopolysaccharide and toll-like receptor (TLR) agonists, as activators of innate immunity, are also responsible for regenerative activity of MSCs by inducing paracrine factors secretion such as VEGF [91]. IFN- γ and TLR also upregulate the glucocorticoids production, which decreases T cells stimulated by radiotherapy in colonic mucosa [92].

Akiyama et al. reported that MSCs induced T cell apoptosis via the Fas/FasL pathway [93]. Telomerase improved immunomodulatory properties of MSCs by upregulating FasL expression [94]. Dental follicle cells and cementoblasts have been reported to trigger apoptosis of ameloblast-lineage cells, as well as Hertwig's epithelial root sheath (HERS)/epithelial rests of Malassez (ERM) cells, via the Fas/FasL pathway during tooth development [95]. FasL regulated the immunomodulatory properties of Human gingiva-derived mesenchymal stem cells (hGMSCs), which is promoted by hypoxia. However, the underlying pathways of such event remain unclear. Further studies regarding the pathways involved in hGMSC-mediated immunomodulation are encouraged.

9. Molecular mechanism of MSCs in hypoxic condition

O₂ concentration in the stem cell niche (usually 2–9% O₂) is considered a driver of cell function [20]. Hypoxia plays a vital role in maintaining homeostasis within the body from the early stage of embryonic development. It facilitates proper embryonic development, maintains stem cell pluripotency, induces differentiation, and regulates the signaling of multiple cascades, including angiogenesis [96]. In hypoxic conditions, these functions are regulated by several

transcription factors such as hypoxia-inducible factors (HIFs), prolyl hydroxylases (PHDs), factor-inhibiting HIF-1 (FIH-1), activator protein 1 (AP-1), nuclear factor (NF)- κ B, p53, and c-Myc [97]. Although interaction among all of the transcription factors is required for cellular response, HIFs (especially HIF-1) are the key regulators of cellular response to hypoxia [98]. The discovery of HIF-1 α by Greg Semenza provided profound insight into the cellular mechanisms that control hypoxic adaptation [99–101].

Generally, under hypoxic conditions, low O₂ level suppresses the prolyl hydroxylation that leads to HIF-1 α accumulation and nuclear translocation [102]. After nuclear translocation, it binds with HIF-1 β to form the heterodimer. Then, the HIF-1 heterodimer binds to a hypoxia-response element (HRE) in the target genes, associated with coactivators such as CBP/p300, and regulates the transcription (**Figure 1**) of as many as 70 genes involved in metabolism, angiogenesis, invasion/metastasis, and cell fate [103].

Figure 1. Regulation of hypoxia in MSCs. HIF, hypoxia-inducible factor; HPH, HIF-prolyl hydroxylases; HPE, HIF-prolyl hydroxylases; HRE, hypoxia-response element; CDK, cyclin-dependent kinase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; IGF, insulin-like growth factor; TNF, tumor necrosis factor; PGE-2, prostaglandin E-2; Gal9, galectin-9. The prolyl hydroxylation process is suppressed due to lack of O₂ that leads HIF-1 α accumulation and nuclear translocation after nuclear translocation, and it binds HIF-1 β to form the heterodimer. Then, the HIF-1 heterodimer binds HRE in the genes target, associated with coactivators such as CBP/p300, and regulates the transcription of as many as 70 genes involved in proliferation, differentiation, and immunomodulatory.

In 2007, iPSCs were discovered by Shinya Yamanaka and colleagues, and the subsequent identification of the necessary transcriptional programs was required to maintain stem cells in a pluripotent state [104, 105]. The measurement of low partial pressures of oxygen in various stem cell niches raises question whether HIF-1 α and iPSCs pathways were converged. It was described initially in Embryonic stem cells (ESCs) [106], hematopoietic stem cells (HSCs) [107], neural stem cells (NSCs) [108], and cancer stem cells (CSCs) [109], which now further expanded to include iPSCs [110]. Remarkably, Yamanaka first reprogrammed fibroblasts to iPSCs using only four transcription factors (Oct4, Sox2, c-Myc, and Klf4) [105] in the same year that Oct4 was shown to be a specific target gene of HIF-2 α [111]. The correlation between HIF-2 α and Oct4 has been proposed as underlying mechanism of stem cells response to hypoxic conditions in their niche and direct modification of stem cell function by low O₂. HIF-2 α expression has recently been investigated in several stem cell lineages, and Oct4 expression is tightly regulated throughout embryogenesis. Loss or even decrease in Oct4 expression leads to differentiation [112]. Oct4 works in concert with Nanog and Sox2 to maintain stem cell identity and repress genes that promote differentiation [113]. The recent identification of HIF-2 α upregulation by Oct4 in CSCs and ESCs underscores the importance of this axis in maintaining stemness in both development and disease.

It is known that phosphorylation of protein kinase B (Akt), a downstream gene of phosphatidylinositol 3-kinase (PI3K) signaling pathway, is an important step in signaling pathways that mediate cell proliferation [114, 115]. In PI3K/Akt pathway, a large number of substrates are phosphorylated, including HIF-1 [116]. Referring to study done by Rosová et al., the preculture of MSCs in hypoxia prior to injection activated the PI3K/Akt signaling pathway while maintaining their viability and cell cycle rates [117].

Hypoxia-mediated MSC differentiation by reducing apoptosis via activating the PI3K/Akt/FoxO pathway. Referring to Wang et al., MSCs underwent apoptosis upon induction for chondrogenic differentiation [118]. Apoptosis has been demonstrated as a general phenomenon that occurs during endochondral differentiation of chondrocytes [119]. One study demonstrated that chondrocytes progression to endochondral ossification employed higher FAS receptor and caspase protein as indicators of apoptosis [120]. Other studies showed that both the Wnt/ β -catenin and Indian hedgehog (Ihh) signaling pathways play important roles in endochondral ossification. β -catenin is needed at upstream of Ihh signaling for chondrocyte survival and inhibition of apoptosis [121]. The expression of Sox9, col2a1 and aggrecan in prechondrogenic cells 30 and chondrocytes 14 is regulated by PI3K/Akt pathway. It has also been demonstrated that PI3K/Akt regulated col2a1 and aggrecan by modulating Sox9 expression and transcriptional activity in nucleus pulposus cells 31.

Lee et al. [122] showed novel pathway for hypoxia-induced proliferation and migration in human mesenchymal stem cells that employ HIF-1 α , FASN, and mTORC1O. Hypoxia treatment stimulates UCB-hMSC proliferation, along with the expression of two lipogenic enzymes: fatty acid synthase (FASN) and stearoyl-CoA desaturase-1 (SCD1). FASN is a key enzyme in UCB-hMSC proliferation and migration. Hypoxia-induced FASN expression was regulated by the HIF-1 α /SCAP/SREBP1 pathway. Mammalian target of rapamycin (mTOR) was phosphorylated by hypoxia, whereas inhibition of FASN by cerulenin suppressed

hypoxia-induced mTOR phosphorylation, as well as UCB-hMSC proliferation and migration. Hypoxia-induced proliferation and migration are significantly inhibited by raptor small interfering RNA. Hypoxia-induced mTOR also regulates CDK2, CDK4, cyclin D1, cyclin E, and F-actin expression as well as c-myc, p-cofilin, profilin, and Rho GTPase. Moreover, hypoxia-induced FASN stimulates FFA production as well as proliferation and migration. Several studies reported that FAS and FA derivatives inhibited and uncoupled oxidative phosphorylation of various cells [123–125]. Palmitic acid treatment rescues inhibition of mTOR phosphorylation as well as restriction of UCB-hMSC proliferation and migration. Change in cellular metabolite ratios may be another pathway, in addition to the HIF1a/SCAP/SREBP1 pathway, involved in the regulation of lipid metabolism in UCB-hMSCs. Some studies reported that alteration of cellular metabolite ratios, such as NADP/NADPH, by hypoxia has also an important role in the regulation of various stem cell functions such as cell cycle and self-renewal activities [126, 127].

10. Hypoxic MSCs in clinical application

MSCs possess anti-inflammatory/immunomodulatory properties, which are utilized in therapeutics development. Clinical studies on efficacy of MSCs have been shown to inhibit lethal, immune-based condition of graft versus host disease [65–70]. Moreover, MSCs derived from adipose, bone marrow, and placenta have the capability to recover ischemic injury by increasing vascularization and reducing inflammation in ischemia-injured hindlimb, lung, heart, and brain [71–73, 128]. These cells have been used in clinical trials to treat ischemic disease [74], and the safety of MSCs has been evaluated [129, 130]. There are several modified approaches, which have been proposed to improve the effect of MSCs on ischemia-related disease, such as over expression of angiogenesis-related genes such as bFGF on MSCs [131], combination with other cells such as endothelial cells [84], antioxidants such as melatonin [132], serum deprivation [72], and cell spheroids [133].

From isolation to engraftment, the MSCs usually pass through two different phases, consisting of *in vitro* culture condition (from isolation to transplantation) and *in vivo* or physiological condition (before isolation and after transplantation). At present, most of the expansion procedures of MSCs are performed under ambient O₂ concentration, where cells are exposed to 20% O₂, which is ~4–10 times more than the concentration of O₂ in their natural niches [134, 135]. Maintaining genetic stability has been a challenge during *in vitro* expansion of MSCs. Increased rates of aneuploidy, double-stranded DNA breakdown, and faster telomere shortening have been reported for MSCs cultured in ambient condition [30]. According to recent review, major causes behind aneuploidy were defective spindle assembly checkpoint, centrosome amplification, and merotelic attachments [136], which are caused by ROS [137]. ROS also acts in acceleration of telomere shortening and DNA breakdown [138, 139]. Correlation between telomere shortening and aneuploidy in embryonic and hepatocellular carcinoma cells has also been reported in recent studies [140, 141]. The higher ROS production due to the increased mitochondrial respiration during expansion of MSCs in ambient O₂ concentration might be the cause behind genetic instability in them. However, cells undergo anaerobic

respiration during hypoxia, which lowers the ROS concentration within the cells. This might reduce the DNA damage, telomere shortening, and aneuploidy which in return may increase the biosafety of stem cell-based therapy.

The ability of stem or progenitor cells to home and engraft into target tissues after transplantation is the key to succeed in clinical application. The degree of homing and engraftment of MSCs in adult recipients is very low [142–144]. Hypoxic culture conditions may also provide a solution for more efficient engraftment. Recently, early passaged mouse BM-MSCs showed better engraftment than late passaged mouse BM-MSCs in *in vivo* model [145]. In other study, hypoxic preconditioned murine MSCs also enhanced skeletal muscle regeneration and improved blood flow and vascular formation compared to normoxic condition [146]. Furthermore, hypoxic conditions cause MSCs to grow faster [30] while maintaining a higher number of rapidly self-renewing cells [40]. Hypoxic environment also upregulated chemokine receptors CXCR4, CXCR7 and CX3CR1 [147, 148], and they may facilitate tissue-specific trafficking of MSCs. Thus, sufficient numbers of MSCs with a higher fraction of rapidly self-renewing cells are suggested, and highly expressed chemokine receptors on their surface can be obtained from the early passages of hypoxic cultures, which could increase the efficiency of damaged tissue-specific migration and engraftment following transplantation.

MSCs cultured under hypoxic conditions also increased in vascular endothelial growth factor receptor 1 (VEGFR1) expression and VEGF- or placental growth factor (PLGF)-dependent migration (Okuyama et al., 2006). Preconditioning with oxygen and combined glucose depletion also increased the survival of stem cell antigen (Sca)-1⁺ cells via PI3K/Akt-dependent caspase-3 downregulation and thereby increased the engraftment rate [149]. In addition to the increase in migration and survival, MSCs with hypoxic preconditioning have also been shown to enhance revascularization after transplantation for hindlimb ischemia [117]. Therefore, culturing MSCs in hypoxic conditions can also be considered as a solution for tissue-specific engraftment.

Hypoxia-stimulated immune regulation of MSCs has been observed in the situation of allogeneic use of BM-MSCs for stimulation of therapeutic angiogenesis. Recent study showed hypoxia-conditioned BM-MSCs from B6 mice repair limb of Balb/c mice compared to normoxic MSCs. Engraftment in allogeneic recipients increased by decreasing NK cells cytotoxicity and the accumulation of host-derived NK cells when transplanted *in vivo*. These allogeneic hypoxia-treated BM-MSCs increased CD31⁺ endothelial cells and α SMA⁺ and desmin⁺ muscle cells, thereby enhancing angiogenesis and restoring muscle structure. Moreover, anti-NK antibodies along with normoxic MSCs enhanced angiogenesis and prevented limb amputation in allogeneic recipients with limb ischemia [150].

Some studies have shown that MSC transplantation contributes to tumor formation *in vivo* [24, 151, 152], whereas Furlani et al. reported that cultured MSCs with spontaneous transformations had no functional effects after intracardiac transplantation [153]. Further studies regarding tumorigenicity and safety of the stem cell-based products are encouraged. However, complexity of cell therapy requires more standards for advanced medicinal products [154]. Thus, especially in the field of regenerative medicine, concrete and specific standards and governmental support systems are necessary to promote their production [154].

11. Perspective of hypoxic MSCs

Hypoxic condition has been confirmed to enhance MSCs proliferation, differentiation, and immune regulatory performance. However, some studies have also reported opposite and negative effects. Different outcomes in each study raise interest in availability of more appropriate methods for cell cultures, which require further study in standardizing the culture of MSCs for use in cell therapy. Optimal conditions for the culture of MSCs have not yet been clearly defined, and it is very crucial to precisely determine the effects of hypoxia on MSCs differentiation, proliferation, and morphology, among other aspects. Moreover, hypoxic MSC-based therapies require a complete understanding of stem cell molecular mechanism. The clarity in stem cell regulation is important for further development such as periodic monitoring of chromosomal stability in culture prior to exposure to human to detect mutations and to prevent transplant-associated tumor formation, and also genetic engineering of physiology of MSCs to acquire better outcome.

12. Conclusion

The growing interest in the potential application of MSCs in regenerative medicine was followed by the several studies measuring the effects of low O₂ levels on the behavior and function of MSCs. Hypoxic condition appears to enhance MSCs proliferation, differentiation, and immune regulatory performance in damaged tissues without affecting its characteristic. However, there are also studies that report on negative effects of hypoxia in MSCs.

Author details

Wahyu Widowati^{1*}, Dwi Davidson Rihibiha², Khie Khiong², M. Aris Widodo³,
Sutiman B. Sumitro⁴ and Indra Bachtiar⁵

*Address all correspondence to: wahyu_w60@yahoo.com

1 Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia

2 Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, Indonesia

3 Laboratory of Pharmacology, Faculty of Medicine, Brawijaya University, Malang, Indonesia

4 Department of Biology, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, Indonesia

5 Stem Cell and Cancer Institute, Jakarta, Indonesia

References

- [1] Friedenstein AJ. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet.* 1970;3:393–403. doi:10.1111/j.1365-2184.1970.tb00347.x.
- [2] Friedenstein AJ. Stromal mechanisms of bone marrow: cloning *in vitro* and retransplantation *in vivo*. *Haematol Blood Transfus.* 1980;25:19–29. doi:10.1007/978-3-642-67319-1_3.
- [3] Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. *Cell Stem Cell.* 2008;2:313–319. doi:10.1016/j.stem.2008.03.002.
- [4] Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *J Cell Physiol.* 2007;213:341–347. doi:10.1002/jcp.21200.
- [5] Kolf CM, Cho E, Tuan RS. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. *Arthritis Res Ther.* 2007;9:204. doi:10.1186/ar2116.
- [6] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999;284:143–147. doi:10.1126/science.284.5411.143.
- [7] Prockop DJ. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). *Clin Pharmacol Ther.* 2007;82:241–243. doi:10.1038/sj.clpt.6100313.
- [8] Rogers I, Casper RF. Umbilical cord blood stem cells. *Best Pract Res Clin Obstet Gynaecol.* 2004;18:893–908. doi:10.1016/j.bpobgyn.2004.06.004.
- [9] Bieback K, Kluter H. Mesenchymal stromal cells from umbilical cord blood. *Curr Stem Cell Res Ther.* 2007;2:310–323.
- [10] Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. *Curr Opin Mol Ther.* 2005;7:300–305. PMID:16121695.
- [11] Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. *J Bone Miner Res.* 2003;18:696–704. doi:10.1359/jbmr.2003.18.4.696.
- [12] Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod.* 2004;19:1450–1456. doi:10.1093/humrep/deh279.
- [13] Bi Y, Ehrichtiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med.* 2007;13:1219–1227. doi:10.1038/nm1630.

- [14] Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, Takashi TA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy*. 2004;6:543–553. doi:10.1080/14653240410005366-1.
- [15] De Bari C, Dell’accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum*. 2001;44:1928–1942. doi:10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.
- [16] Crisan M, Deasy B, Gavina M, Zheng B, Huard J, Lazzari L, et al. Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes. *Methods Cell Biol*. 2008;86:295–309. doi:10.1016/S0091-679X(08)00013-7.
- [17] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the international society for cellular therapy position statement. *Cytotherapy*. 2006;8:315–317. doi:10.1080/14653240600855905.
- [18] Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. *Blood*. 2004;103:1662–1668. doi:10.1182/blood-2003-09-3070.
- [19] Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. *Arthritis Rheum*. 2002;46:3349–3360. doi:10.1002/art.10696.
- [20] Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. *Nat Rev Mol Cell Biol*. 2008;9:285–296. doi:10.1038/nrm2354.
- [21] Scadden DT. The stem-cell niche as an entity of action. *Nature*. 2006;441:1075–1079. doi:10.1038/nature04957.
- [22] Cooper PD, Burt AM, Wilson JN. Critical effect of oxygen tension on rate of growth of animal cells in continuous suspended culture. *Nature*. 1958;182:1508–1509. doi:10.1038/1821508b0.
- [23] Zwartouw HT, Westwood JC. Factors affecting growth and glycolysis in tissue culture. *Br J Exp Pathol*. 1958;39:529–539.
- [24] Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. *Stem Cells*. 2006;24:1095–1093. doi:10.1634/stemcells.2005-0403.
- [25] Kuhn NZ, Tuan RS. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. *J Cell Physiol*. 2010;222:268–277. doi:10.1002/jcp.21940.

- [26] Harrison JS, Rameshwar P, Chang V, Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. *Blood*. 2002;99:394. PMID:11783438.
- [27] Kofoed H, Sjøtoft E, Siemssen SO, Olesen HP. Bone marrow circulation after osteotomy. Blood flow, pO₂, pCO₂, and pressure studied in dogs. *Acta Orthop Scand*. 1985;56:400–403.
- [28] Matsumoto A, Matsumoto S, Sowers AL, Koscielniak JW, Trigg NJ, Kuppusamy P, et al. Absolute oxygen tension (pO₂) in murine fatty and muscle tissue as determined by EPR. *Magn Reson Med*. 2005;54:1530–1535. doi:10.1002/mrm.20714.
- [29] Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. *Diabetes*. 2009;58:718–725. doi:10.2337/db08-1098.
- [30] Estrada JC, Albo C, Benguria A, Dopazo A, Lopez-Romero P, Carrera-Quintanar L, et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. *Cell Death Differ*. 2012;19:743–755. doi:10.1038/cdd.2011.172.
- [31] Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitering S, Kloss F, et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. *Aging Cell*. 2007;6:745–757. doi:10.1111/j.1474-9726.2007.00336.x.
- [32] Mohamadnejad M, Pournasr B, Bagheri M, Aghdami N, Shahsavani M, Hosseini LA, et al. Transplantation of allogeneic bone marrow mesenchymal stromal cell-derived hepatocyte-like cells in homozygous familial hypercholesterolemia. *Cytotherapy*. 2010;12:566–568. doi:10.3109/14653240903511143.
- [33] Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med*. 2006;355:1210–1221.
- [34] Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, Kerst G, et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. *BMC Cell Biol*. 2010;11:1–11. doi:10.1186/1471-2121-11-11.
- [35] Nekanti U, Dastidar S, Venugopal P, Totey S, Ta M. Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia. *Int J Biol Sci*. 2010;6:499–512.
- [36] Widowati W, Wijaya L, Murti H, Widyastuti H, Agustina D, Laksmiawati DR, et al. Conditioned medium from normoxia (WJMSCs-norCM) and hypoxia-treated WJMSCs (WJMSCs-hypoCM) in inhibiting cancer cell proliferation. *BGM*. 2015;7:8–17.

- [37] Basciano L, Nemos C, Foliguet L, de Isla N, de Carvalho M, Tran N, et al. Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. *BMC Cell Biol.* 2011;12:1–12. doi:10.1186/1471-2121-12-12.
- [38] Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. *Biochem Biophys Res Commun.* 2007;358:948–953. doi:10.1016/j.bbrc.2007.05.054.
- [39] Weijers EM, Van Den Broek LJ, Waaijman T, Van Hinsbergh VWM, Gibbs S, Koolwijk P. The influence of hypoxia and fibrinogen variants on the expansion and differentiation of adipose tissue-derived mesenchymal stem cells. *Tissue Eng Part A.* 2011;17:2675–2685. doi:10.1089/ten.tea.2010.0661.
- [40] Saller MM, Prall WC, Docheva D, Schönlitzer V, Popov T, Anz D, et al. Increased stemness and migration of human mesenchymal stem cells in hypoxia is associated with altered integrin expression. *Biochem Biophys Res Commun.* 2012;423:379–385. doi:10.1016/j.bbrc.2012.05.134.
- [41] Widowati W, Wijaya L, Bachtiar I, Gunanegara RF, Sugeng SU, Irawan YA, et al. Effect of oxygen tension on proliferation and characteristics of Wharton's jelly-derived mesenchymal stem cells. *BGM.* 2014;6:43–48. doi:10.1016/j.bgm.2014.02.001.
- [42] Pattappa G, Thorpe SD, Jegard NC, Heywood HK, de Bruijn JD, Lee DA. Continuous and uninterrupted oxygen tension influences the colony formation and oxidative metabolism of human mesenchymal stem cells. *Tissue Eng Part C Methods.* 2013;19:68–79. doi:10.1089/ten.TEC.2011.0734.
- [43] Yew TL, Chang MC, Hsu YT, He FY, Weng WH, Tsai CC, et al. Efficient expansion of mesenchymal stem cells from mouse bone marrow under hypoxic conditions. *J Tissue Eng Regen Med.* 2013;7:984–993. doi:10.1002/term.1491.
- [44] Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. *Cancer Res.* 2005;65:3035–3039. doi:10.1158/0008-5472.CAN-04-4194.
- [45] Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term *in vitro* culture and do not exhibit telomere maintenance mechanisms. *Cancer Res.* 2007;67:9142–9149. doi:10.1158/0008-5472.CAN-06-4690.
- [46] Zhang ZX, Guan LX, Zhang K, Wang S, Cao PC, Wang YH, et al. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged *in vitro*. *Cell Biol Int.* 2007;31:645–648. doi:10.1016/j.cellbi.2006.11.025.
- [47] Fischer U, Radermacher J, Mayer J, Mehraein Y, Meese E, et al. Tumor hypoxia: impact on gene amplification in glioblastoma. *Int J Oncol.* 2008;33:509–515. doi:10.3892/ijo_00000034.

- [48] Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. *Mol Cell*. 1998;2:259–265. doi:10.1016/S1097-2765(00)80137-9.
- [49] Ueyama H, Horibe T, Hinotsu S, Tanaka T, Inoue T, Urushihara H, et al. Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. *J Cell Mol Med*. 2012;16:72–82. doi:10.1111/j.1582-4934.2011.01303.x.
- [50] Sutherland GR. Chromosomal fragile sites. *Genet Anal Biomol Eng*. 1991;8:161–166. doi:10.1016/1050-3862(91)90056-W.
- [51] Lukusa T, Fryns JP. Human chromosome fragility. *Biochim Biophys Acta*. 2008;1779:3–16. doi:10.1016/j.bbagr.2007.10.005.
- [52] Nowinski GP, Van Dyke DL, Tilley BC, Jacobsen G, Babu VR, Worsham MJ, et al. The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history. *Am J Hum Genet*. 1990;46:1101–1111. PMID:PMC1683821.
- [53] Pierre RV, Hoagland HC. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. *Cancer*. 1972;30:889–894. doi:10.1002/1097-0142(197210)30:4<889::AID-CNCR2820300405>3.0.CO;2-1.
- [54] Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. *J Cell Mol Med*. 2004;8:301–316. doi:10.1111/j.1582-4934.2004.tb00320.x.
- [55] Hung SP, Ho JH, Shih YR, Lo T, Lee OK. Hypoxia promotes proliferation and osteogenic differentiation potentials of human mesenchymal stem cells. *J Orthop Res*. 2012;30:260–266. doi:10.1002/jor.21517.
- [56] Huang J, Deng F, Wang L, Xiang XR, Zhou WW, Hu N, et al. Hypoxia induces osteogenesis related activities and expression of core binding factor alpha1 in mesenchymal stem cells. *Tohoku J Exp Med*. 2011;224:7–12. doi:10.1620/tjem.224.7.
- [57] Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on *in vitro* and *in vivo* osteochondrogenesis. *J Cell Physiol*. 2001;187:345–355. doi:10.1002/jcp.1081.
- [58] Fink T, Abildtrup L, Fogd K, Abdallah BM, Kassem M, Ebbesen P, Zachar V. Induction of adipocyte like phenotype in human mesenchymal stem cells by hypoxia. *Stem Cells*. 2004;22:1346–1355. doi:10.1634/stemcells.2004-0038.
- [59] Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. *Biochem Biophys Res Commun*. 2006;347:12–21. doi:10.1016/j.bbrc.2006.05.169.
- [60] Potier E, Ferreira E, Andriamanalijaona R, Pujol JP, Oudina K, Logeart-Avramoglou D, et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation

- and angiogenic factor expression. *Bone*. 2007;40:1078–1087. doi:10.1016/j.bone.2006.11.024.
- [61] Georgi N, Cillero-Pastor B, Eijkel GB, Periyasamy PC, Kiss A, van Blitterswijk C, et al. Differentiation of mesenchymal stem cells under hypoxia and normoxia: lipid profiles revealed by time-of-flight secondary ion mass spectrometry and multivariate analysis. *Anal Chem*. 2015;87:3981–3988. doi:10.1021/acs.analchem.5b00114.
- [62] Maumus M, Manferdini C, Toupet K, Peyrafitte JA, Ferreira R, Facchini A, et al. Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis. *Stem Cell Res*. 2013;11:834–844. doi:10.1016/j.scr.2013.05.008.
- [63] Brown AJ. Cholesterol, statins and cancer. *Clin Exp Pharmacol Physiol*. 2007;34:135–141. doi:10.1111/j.1440-1681.2007.04565.x.
- [64] Simonaro CM, Sachot S, Ge Y, He X, Deangelis VA, Eliyahu E, et al. Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. *PLoS One* 2013;8:1–14. doi:10.1371/journal.pone.0062715.
- [65] Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Le Blanc K. Mesenchymal stem cells for treatment of therapy resistant graft versus host disease. *Transplant*. 2006;81:1390–1397. doi:10.1097/01.tp.0000214462.63943.14.
- [66] Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft versus host disease with third party haploidentical mesenchymal stem cells. *Lancet*. 2004;363:1439–1441. doi:10.1016/S0140-6736(04)16104-7.
- [67] Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft versus host disease: a phase II study. *Lancet*. 2008;371:1579–1586. doi:10.1016/S0140-6736(08)60690-X.
- [68] Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. *Leukemia*. 2008;22:593–599. doi:10.1038/sj.leu.2405090.
- [69] Ball L, Bredius R, Lankester A, Schweizer J, van den Heuvel-Eibrink M, Escher H, et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. *Leukemia*. 2008;22:1256–1257. doi:10.1038/sj.leu.2405013.
- [70] Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. *Blood Cells Mol Dis*. 2008;40:25–32. doi:10.1016/j.bcmd.2007.06.021.

- [71] Liu J, Hao H, Xia L, Ti D, Huang H, Dong L, et al. Hypoxia pretreatment of bone marrow mesenchymal stem cells facilitates angiogenesis by improving the function of endothelial cells in diabetic rats with lower ischemia. *PLoS One*. 2015;10:1–18. doi:10.1371/journal.pone.0126715.
- [72] Sun CK, Leu S, Hsu SY, Zhen YY, Chang LT, Tsai CY, et al. Mixed serum-derived and normal adipose-derived mesenchymal stem cells against acute lung ischemia reperfusion injury in rats. *Am J Transl Res*. 2015;7:209–231.
- [73] Zhang GW, Gu TX, Guan XY, Sun XJ, Jiang DQ, Tang R, Qi X, Li XY. Delayed enrichment for c-kit and inducing cardiac differentiation attenuated protective effects of BMSCs transplantation in pig model of acute myocardial ischemia. *Cardiovasc Ther*. 2015;33:184–192. doi:10.1111/1755-5922.12131.
- [74] Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. *Cytotherapy*. 2014;16:245–257. doi:10.1016/j.jcyt.2013.11.011.
- [75] Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. *Clin Sci*. 2013;124:165–176. doi:10.1042/CS20120226.
- [76] Skurkovich B, Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. *Curr Opin Mol Ther*. 2003;5:52–57. PMID:12669471.
- [77] Croitoru-Lamoury J, Lamoury FMJ, Caristo M, Suzuki K, Walker D, Takikawa O, et al. Interferon- γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). *PLoS One*. 2011;6:1–13. doi:10.1371/journal.pone.0014698.
- [78] Rong LJ, Chi Y, Yang SG, Chen DD, Chen F, Xu SX, et al. Effects of interferon- γ on biological characteristics and immunomodulatory property of human umbilical cord-derived mesenchymal stem cells. *J Exp hematol Chin Assoc Pathophysiol*. 2012;20:421–426.
- [79] Kang JW, Koo HC, Hwang SY, Kang SK, Ra JC, Lee MH, et al. Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells. *J Vet Sci*. 2012;13:23–31. doi:10.4142/jvs.2012.13.1.23.
- [80] Lin W, Oh SKW, Choo ABH, George AJT. Activated T cells modulate immunosuppression by embryonic- and bone marrow-derived mesenchymal stromal cells through a feedback mechanism. *Cytotherapy*. 2012;14:274–284. doi:10.3109/14653249.2011.635853.
- [81] Roemeling-Van Rhijn M, Mensah FKF, Korevaar SS, Leijds MJC, Van Osch GJVM, IJzermans JNM, et al. Effects of hypoxia on the immunomodulatory properties of

- adipose tissue-derived mesenchymal stem cells. *Front Immunol.* 2013;4:1–8. doi:10.3389/fimmu.2013.00203.
- [82] English K, Tonlorenzi R, Cossu G, Wood KJ. Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways. *Stem Cells Dev.* 2013;22:512–523. doi:10.1089/scd.2012.0386.
- [83] Engela AU, Baan CC, Peeters AM, Weimar W, Hoogduijn MJ. Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells. *Cell Transplant.* 2013;22:41–54. doi:10.3727/096368912X636984.
- [84] Huang CC, Chen DY, Wei HJ, Lin KJ, Wu CT, Lee TY, et al. Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs. *Biomaterials.* 2013;34:9441–9550. doi:10.1016/j.biomaterials.2013.09.010.
- [85] Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. *Stem Cells Dev.* 2010;19:1803–1809. doi:10.1089/scd.2009.0418.
- [86] Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. *Clin Exp Immunol.* 2007;149:353–363. doi:10.1111/j.1365-2249.2007.03422.x.
- [87] Noone C, Kihm A, English K, O'Dea S, Mahon BP. IFN-gamma stimulated human umbilical-tissue derived cells potently suppress NK activation and resist NK mediated cytotoxicity *in vitro*. *Stem Cells Dev.* 2013;15:3003–3014. doi:10.1089/scd.2013.0028.
- [88] Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. *Eur J Immunol.* 2013;43:2741–2749. doi:10.1002/eji.201343335.
- [89] Kwon YW, Heo SC, Jeong GO, Yoon JW, Mo WM, Lee MJ, et al. Tumor necrosis factor- α -activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. *Biochim Biophys Acta.* 2013;1832:2136–2144. doi:10.1016/j.bbadis.2013.08.002.
- [90] Lu Z, Wang G, Dunstan CR, Chen Y, Lu WYR, Davies B, et al. Activation and promotion of adipose stem cells by tumour necrosis factor-alpha preconditioning for bone regeneration. *J Cell Physiol.* 2013;228:1737–1744. doi:10.1002/jcp.24330.
- [91] Grote K, Petri M, Liu C, Jehn P, Spalthoff S, Kokemüller H, et al. Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors. *Eur Cells Mater.* 2013;26:66–79. PMID:24027020.
- [92] Bessout R, Sémont A, Demarquay C, Charcosset A, Benderitter M, Mathieu N. Mesenchymal stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC immunomodulation. *Mucosal Immunol.* 2014;7:656–669. doi:10.1038/mi.2013.85.

- [93] Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal stem cell induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. *Cell Stem Cell*. 2012;10:544–555. doi:10.1016/j.stem.2012.03.007.
- [94] Chen C, Akiyama K, Yamaza T, You Y-O, Xu X, Li B, et al. Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression. *EMBO Mol Med*. 2014;6:322–334. doi:10.1002/emmm.201303000.
- [95] Ding, SW. RNA-based antiviral immunity. *Nat Rev Immunol*. 2010;10:632–644. doi:10.1038/nri2824.
- [96] Lin Q, Kim Y, Alarcon RM, Yun Z. Oxygen and cell fate decisions. *Gene Regul Syst Bio*. 2008;2:43–51. PMCID:PMC2733087.
- [97] Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. *Biochem J*. 2008;414:19–29. doi:10.1042/BJ20081055.
- [98] Stamati K, Mudera V, Cheema U. Evolution of oxygen utilization in multicellular organisms and implications for cell signalling in tissue engineering. *J Tissue Eng*. 2011;2:1–12. doi:10.1177/2041731411432365.
- [99] Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol*. 1992;12:5447–5454.
- [100] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia inducible factor 1 is a basic helix loop helix PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci*. 1995;92:5510–5514. PMCID:PMC46495.
- [101] Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci*. 1993;90:4304–4308. PMCID:PMC46495.
- [102] Weidemann A, Johnson RS. Biology of HIF-1 α . *Cell Death Differ*. 2008;15:621–627. doi:10.1038/cdd.2008.12.
- [103] Brahimi-Horn MC, Pouyssegur J. Oxygen, a source of life and stress. *FEBS Lett*. 2007;581:3582–3591. doi:10.1016/j.febslet.2007.06.018.
- [104] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131:861–872. doi:10.1016/j.cell.2007.11.019.
- [105] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126:663–676. doi:10.1016/j.cell.2006.07.024.
- [106] Adelman DM, Maltepe E, Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. *Genes Dev*. 1999;13:2478–2483.

- [107] Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. *Blood*. 1993;8:2031–2037. PMID:8104535.
- [108] Panchision DM. The role of oxygen in regulating neural stem cells in development and disease. *J Cell Physiol*. 2009;220:562–568. doi:10.1002/jcp.21812.
- [109] Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer Cell*. 2009;15:501–513. doi:10.1016/j.ccr.2009.03.018.
- [110] Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. *Cell Stem Cell*. 2009;5:237–241. doi:10.1016/j.stem.2009.08.001.
- [111] Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, et al. HIF-2 α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. *Genes Dev*. 2006;20:557–570. doi:10.1101/gad.1399906.
- [112] Boiani M, Eckardt S, Scholer HR, McLaughlin KJ. Oct4 distribution and level in mouse clones: consequences for pluripotency. *Genes*. 2002;16:1209–1219. doi:10.1101/gad.966002.
- [113] Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell*. 2005;122:947–956. doi:10.1016/j.cell.2005.08.020.
- [114] Borgatti P, Martelli AM, Bellacosa A, Casto R, Massari L, Capitani S, et al. Translocation of AKT/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. *FEBS Lett*. 2000;477:27–32.
- [115] Jung F, Haendeler J, Goebel C, Zeiher AM, Dimmeler S. Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. *Cardiovasc Res*. 2000;48:148–157. doi:10.1016/S0008-6363(00)00152-8.
- [116] Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer*. 2003;3:721–732. doi:10.1038/nrc1187.
- [117] Rosová I, Dao M, Capoccia B, Link D, Nolte JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. *Stem Cells*. 2008;26:2173–2182. doi:10.1634/stemcells.2007-1104.
- [118] Wang CY, Chen LL, Kuo PY, Chang JL, Wang YJ, Hung SC. Apoptosis in chondrogenesis of human mesenchymal stem cells: effect of serum and medium supplements. *Apoptosis*. 2010;15:439–449. doi:10.1007/s10495-009-0431-x.
- [119] Cheung JO, Grant ME, Jones CJ, Hoyland JA, Freemont AJ, Hillarby MC. Apoptosis of terminal hypertrophic chondrocytes in an *in vitro* model of endochondral ossification. *J Pathol*. 2003;201:496–503. doi:10.1002/path.1462.

- [120] Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor- α . *J Orthop Res*. 2001;19:785–796. doi:10.1016/S0736-0266(00)00078-4.
- [121] Mak KK, Chen MH, Day TF, Chuang PT, Yang Y. Wnt/ β -catenin signaling interacts differentially with *Ihh* signaling in controlling endochondral bone and synovial joint formation. *Development*. 2006;133:3695–3707. doi:10.1242/dev.02546.
- [122] Lee HJ, Ryu JM, Jung YH, Oh SY, Lee SJ, Han HJ. Novel pathway for hypoxia-induced proliferation and migration in human mesenchymal stem cells: involvement of HIF-1 α , FASN, and mTORC1. *Stem Cells*. 2015;33:2182–2195. doi:10.1002/stem.2020.
- [123] Ventura FV, Ruiter JP, Ijlst L, Almeida IT, Wanders RJ. Inhibition of oxidative phosphorylation by palmitoyl-CoA in digitonin permeabilized fibroblasts: implications for long-chain fatty acid β oxidation disorders. *Biochim Biophys Acta*. 1995;1272:14–20.
- [124] Samartsev VN, Belosludtsev KN, Chezganova SA, Zeldi IP. Effect of ethanol on the palmitate induced uncoupling of oxidative phosphorylation in liver mitochondria. *Biochemistry*. 2002;67:1240–1247. doi:10.1023/A:1021397220815.
- [125] Brustovetskii NN, Dedukhova VN, Egorova MV, Mokhova EN, Skulachev VP. Uncoupling of oxidative phosphorylation by fatty acids and detergents suppressed by ATP/ADP antiporter inhibitors. *Biokhimiia*. 1991;56:1042–1048.
- [126] Cipolleschi MG, Marzi I, Santini R, Fredducci D, Vinci MC, D'Amico M, et al. Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets. *Cell Cycle*. 2014;13:268–278. doi:10.4161/cc.27031.
- [127] Marzi I, Cipolleschi MG, D'Amico M, Stivarou T, Rovida E, Vinci MC, et al. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming. *Cell Cycle*. 2013;12:353–364. doi:10.4161/cc.23200.
- [128] Li D, Zhang M, Zhang Q, Wang Y, Song X, Zhang Q. Functional recovery after acute intravenous administration of human umbilical cord mesenchymal stem cells in rats with cerebral ischemia-reperfusion injury. *Intractable Rare Dis Res*. 2015;4:98–104. doi:10.5582/iridr.2015.01010.
- [129] Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomeri JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Arch Neurol*. 2010;67:1187–1194. doi:10.1001/archneurol.2010.248.
- [130] Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (safe cell): a systematic review and meta-analysis of clinical trials. *PLoS One*. 2012;7:1–21. doi:10.1371/journal.pone.0047559.

- [131] Zhang JC, Zheng GF, Wu L, Ou Yang LY, Li WX. Bone marrow mesenchymal stem cells overexpressing human basic fibroblast growth factor increase vasculogenesis in ischemic rats. *Braz J Med Biol Res.* 2014;47:886–894. doi:10.1590/1414-431X20143765.
- [132] Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, et al. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. *J Pineal Res.* 2013;54:207–221. doi:10.1111/jpi.12020.
- [133] Park IS, Chung PS, Ahn JC. Enhanced angiogenic effect of adipose-derived stromal cell spheroid with low-level light therapy in hind limb ischemia mice. *Biomaterials.* 2014;35:9280–9289. doi:10.1016/j.biomaterials.2014.07.061.
- [134] Antoniou ES, Sund S, Homsy EN, Challenger LF, Rameshwar P. A theoretical simulation of hematopoietic stem cells during oxygen fluctuations: prediction of bone marrow responses during hemorrhagic shock. *Shock.* 2004;22:415–422.
- [135] Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO₂ distributions in the bone marrow hematopoietic compartment II. Modified Kroghian models. *Biophys J.* 2001;81:685–696. doi:10.1016/S0006-3495(01)75733-5.
- [136] Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. *Nat Rev Genet.* 2012;13:189–203. doi:10.1038/nrg3123.
- [137] Wang CY, Liu LN, Zhao ZB. The role of ROS toxicity in spontaneous aneuploidy in cultured cells. *Tissue Cell.* 2012;45:47–53. doi:10.1016/j.tice.2012.09.004.
- [138] Barzilai A, Yamamoto K. DNA damage responses to oxidative stress. *DNA Repair (Amst).* 2004;3:1109–1115. doi:10.1016/j.dnarep.2004.03.002.
- [139] Guachalla LM, Rudolph KL. ROS induced DNA damage and checkpoint responses: influences on aging? *Cell Cycle.* 2010;9:4058–4060. doi:10.4161/cc.9.20.13577.
- [140] Treff NR, Su J, Taylor D, Scott RT. Telomere DNA deficiency is associated with development of human embryonic aneuploidy. *PLoS Genetics.* 2011;7:1–10. doi:10.1371/journal.pgen.1002161.
- [141] Plentz RR, Schlegelberger B, Flemming P, Gebel M, Kreipe H, Manns MP, et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. *Hepatology.* 2005;42:522–526. doi:10.1002/hep.20847.
- [142] LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. *Cell.* 2002;111:589–601. doi:10.1016/S0092-8674(02)01078-4.
- [143] Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. *Trends Mol Med.* 2010;16:203–209. doi:10.1016/j.molmed.2010.02.005.
- [144] Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of trans differentiation and modes of tissue repair—current views. *Stem Cells.* 2007;25:2896–2902. doi:10.1634/stemcells.2007-0637.

- [145] Jin J, Zhao Y, Tan X, Guo C, Yang Z, Miao D. An improved transplantation strategy for mouse mesenchymal stem cells in an acute myocardial infarction model. *PLoS One*. 2011;6:1–16. doi:10.1371/journal.pone.0021005.
- [146] Leroux L, Descamps B, Tojais NF, Seguy B, Oses P, Moreau C, et al. Hypoxia preconditioned mesenchymal stem cells improve vascular and skeletal muscle fiber regeneration after ischemia through a wnt4-dependent pathway. *Mol Ther*. 2010;18:1545–1552. doi:10.1038/mt.2010.108.
- [147] Liu H, Liu S, Li Y, Wang X, Xue W, Ge G, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. *PLoS One*. 2012;7:1–13. doi:10.1371/journal.pone.0034608.
- [148] Hung S-C, Pochampally RR, Hsu S-C, Sanchez C, Chen S-C, Spees J, et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment *in vivo*. *PLoS One*. 2007;2:1–11. doi:10.1371/journal.pone.0000416.
- [149] Lu G, Haider HK, Jiang S, Ashraf M. Sca-1⁺ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning induced connexin-43. *Circulation*. 2009;119:2587–2596. doi:10.1161/CIRCULATIONAHA.108.827691.
- [150] Huang WH, Chen HL, Huang PH, Yew TL, Lin MW, Lin SJ, et al. Hypoxic mesenchymal stem cells engraft and ameliorate limb ischaemia in allogeneic recipients. *Cardiovasc Res*. 2014;101:266–276. doi:10.1093/cvr/cvt250.
- [151] Guest I, Ilic Z, Ma J, Grant D, Glinsky G, Sell S. Direct and indirect contribution of bone marrow-derived cells to cancer. *Int J Cancer*. 2010;126:2308–2318. doi:10.1002/ijc.24946.
- [152] Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. Sarcoma derived from cultured mesenchymal stem cells. *Stem Cells*. 2007;25:371–379. doi:10.1634/stemcells.2005-0620.
- [153] Furlani D, Li W, Pittermann E, Klopsch C, Wang L, Knopp A, et al. A transformed cell population derived from cultured mesenchymal stem cells has no functional effect after transplantation into the injured heart. *Cell Transplant*. 2009;18:319–331. doi:10.3727/096368909788534906.
- [154] Tsubouchi M, Matsui S, Banno Y, Kurokawa K, Kawakami K. Overview of the clinical application of regenerative medicine products in Japan. *Health Policy*. 2008;88:62–72. doi:10.1016/j.healthpol.2008.02.011.